Trial result ·
Mutant p53 reactivation and DNA demethylation in the treatment of AML/MDS.
Written based on 1 research study on PubMed, searched on 5 Nov 2026.
What was studied
This study looked at leukemia and bone marrow disease with p53 gene changes. These cancers resist many standard drugs. The team tested arsenic trioxide with decitabine. They used cell tests, mice and a first-in-human pilot trial. They also studied samples from 103 patients with p53 changes.
What they found
The drugs together killed p53-mutant leukemia cells. They also slowed tumor growth in mice. In the pilot trial, the plan caused manageable adverse events. Some treated patients reached complete remission in the bone marrow. This went with p53 activation and an interferon response. Among the 103 samples, 48 different p53 changes were found. Of these, 21 were judged to fit the plan.
What it means for patients
The authors say this study sets out an alternative plan for patients with p53-mutant disease. They say it gives proof of concept for p53-targeted therapy. This therapy would tell p53 changes apart.
Why it is not certain yet
The human trial was a pilot study. The abstract describes no comparison group for the pilot trial. Much of the work used cells and mice. These results may not carry over to patients. The abstract does not report survival.
Source
Mutant p53 reactivation and DNA demethylation in the treatment of AML/MDS.
PubMed · PMID 42585289We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Myelodysplastic syndromes publications